Nuclear envelope changes and liver cancer risk in chronic liver disease
Official title: Nuclear envelope and predisposition to hepatic neoplasia
Funded at Hackensack University Medical Center · NIH-11377376 · Data updated 2026-11-12
Aims to understand how changes in the cell’s nuclear envelope may raise the risk of liver cancer in people with chronic liver disease.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Hackensack University Medical Center NIH-funded |
| Lab location | 1 site (Hackensack, United States) |
| Project start | August 1, 2023 |
| Project end | July 31, 2028 |
| Funding year | 2026 |
| Award (this year) | $405,116 |
| NIH project number | 5R01CA283566-05 |
| Project ID | NIH-11377376 on NIH RePORTER |
Who could benefit from this research
✓Could help
Patients with chronic liver disease at risk for hepatocellular carcinoma, or those undergoing liver tissue sampling or biopsy for research.
✕Less likely to help
Individuals without chronic liver disease or not at risk for liver cancer are unlikely to benefit directly.
What this research studies
This project looks at how alterations in LAP1, a key nuclear envelope protein, might push liver cells toward cancer in people with chronic liver diseases like nonalcoholic steatohepatitis. The researchers will study LAP1’s isoform switching during cell differentiation and its link to liver cancer in mouse models and human tissue samples. They have preliminary data showing LAP1 depletion can cause liver tumors and fetal gene activation, suggesting a new mechanism for hepatocellular carcinoma development. The study combines cellular, genetic, and animal model approaches to uncover how nuclear envelope changes influence hepatocyte behavior and cancer risk.
Why it matters
Potential benefit: Understanding this mechanism could identify new targets to prevent or detect liver cancer early in patients with chronic liver disease.
How similar studies have gone: Earlier work linked LAP1 to lipid metabolism and tumor formation in mice, with emerging data supporting a role in liver cancer predisposition.
Where this research is happening
-
Hackensack University Medical Center
Hackensack, United States Active
Researchers
- Principal investigator: Shin, Ji-Yeon — Hackensack University Medical Center
- Study coordinator: Shin, Ji-Yeon
Related research
Other NIH-funded projects on the same topics.
-
Orally accessible antiviral leaders to fight COVID-19 and related coronaviruses
A research effort to fast-track safe, easy-to-take oral drugs that can treat COVID-19 and other coronaviruses by repurposing and optimizing existing antiviral compounds.
-
Metropolitan Antiviral Drug Accelerator Virology Core
A core team across top hospitals and universities is testing antiviral compounds against SARS-CoV-2 and related coronaviruses to identify promising drugs for COVID-19.
-
Broad-spectrum SARS-CoV-2 protease inhibitor for antiviral therapy
Researchers are developing a new small-molecule drug that blocks a key SARS-CoV-2 enzyme, with potential to treat COVID-19 across multiple virus variants.
-
Metropolitan AntiViral Drug Accelerator: Animal Models
A large NIH-funded effort uses animal models to test new antiviral compounds against SARS-CoV-2 and related viruses to move promising leads toward early development.
-
Metropolis AntiViral Drug Accelerator: Pharmacology Core
A dedicated program to speed up promising antiviral drugs by testing their behavior in the body and choosing the best candidates for further development.
-
Metropolitan Antiviral Drug Accelerator
A national program at Hackensack University Medical Center to help develop and optimize small-molecule drugs that may block key SARS-CoV-2 proteins, potentially slowing COVID-19 replication.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.